| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
CVRx, Inc.
13D/A
CVRX · 126638105
|
0.6% |
10/2/2026
Event 9/30/2026
|
||||
|
Neuronetics, Inc.
13D/A
STIM · 64131A105
|
13.9% |
8/24/2026
Event 8/14/2026
|
||||
|
SEACOR Marine Holdings Inc.
13D
SMHI · 78413P101
|
7.2% |
6/22/2026
Event 6/22/2026
|
||||
| Schedule 13G · 16 securities · passive | ||||||
|
WW International, Inc.
13G/A
WW · 98262P200
|
7.5% |
8/26/2026
Event 8/26/2026
|
||||
|
Kazia Therapeutics Ltd
13G/A
KZIA · 48669G105
|
19.6% |
8/19/2026
Event 8/5/2026
|
||||
|
Mobilicom Ltd
13G
MOB · Q6297L120
|
6.4% |
7/15/2026
Event 4/28/2026
|
||||
|
Exagen Inc.
13G/A
XGN · 30068X103
|
9.9% |
5/20/2026
Event 3/31/2026
|
||||
|
IO Biotech, Inc.
13G/A
IOBTQ · 449778109
|
0% |
5/20/2026
Event 3/31/2026
|
||||
|
CalciMedica, Inc.
13G/A
CALC · 38942Q202
|
0% |
5/20/2026
Event 3/31/2026
|
||||
|
Adagene Inc.
13G
ADAG · 005329107
|
5.1% |
3/18/2026
Event 3/16/2026
|
||||
|
Oncology Institute, Inc.
13G/A
DFPH · 23343Q100
|
10.2% |
3/16/2026
Event 3/13/2026
|
||||
|
Airsculpt Technologies, Inc.
13G/A
AIRS · 009496100
|
10.8% |
3/4/2026
Event 3/2/2026
|
||||
|
OKYO Pharma Ltd
13G/A
OKYO · G6724L116
|
9.5% |
2/13/2026
Event 12/31/2025
|
||||
|
Neuronetics, Inc.
13G/A
64131A1051
|
9.9% |
2/4/2026
Event 1/30/2026
|
||||
|
Traws Pharma, Inc.
13G
TRAW · 68232V884
|
6.8% |
1/16/2026
Event 1/14/2026
|
||||
|
Tiziana Life Sciences Ltd
13G/A
TLSA · 88875G101
|
5.4% |
12/10/2025
Event 9/30/2025
|
||||
|
Lineage Cell Therapeutics, Inc.
13G
LCTX · 53566P109
|
5.0% |
9/26/2025
Event 9/22/2025
|
||||
|
Femasys Inc.
13G/A
FEMY · 31447E105
|
9.3% |
8/5/2025
Event 6/30/2025
|
||||
|
AEON Biopharma, Inc.
13G
AEON · 00791X209
|
9.9% |
5/30/2025
Event 5/27/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.